Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in mycobacterium tuberculosis isolates from southern China

Journal of Clinical Microbiology

Volumn 52, Issue 1, 2014, Pages 291-297

  Tan, Yaoju ^a   Hu, Zuqiong ^a   Zhang, Tianyu ^b   Cai, Xingshan ^a   Kuang, Haobin ^a   Liu, Yanwen ^a   Chen, Junyu ^a   Yang, Feng ^b   Zhang, Ke ^b   Tan, Shouyong ^a   Zhao, Yanlin ^c  

^a GUANGZHOU CHEST HOSPITAL   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; DNA; PROTEIN PNCA; PYRAZINAMIDE; RPSA PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; CHINA; CONTROLLED STUDY; DNA FLANKING REGION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; LABORATORY DEVICE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PNCA GENE; PRIORITY JOURNAL; RPSA GENE;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; CHINA; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIBOSOMAL PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84891535256     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01903-13     Document Type: Article

References (37)

1. Heifets L, Lindholm-Levy P. 1992. Pyrazinamide sterilizing activity in vitro against semi-dormant Mycobacterium tuberculosis bacterial populations. Am. Rev. Respir. Dis. 145:1223-1225. http://dx.doi.org/10.1164/ajrccm/145.5.1223.
2. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667. http://dx.doi.org/10. 1038/nm0696-662.
3. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: A review. Int. J. Tuberc. Lung Dis. 7:6-21.
4. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. 1997. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber. Lung Dis. 78:117-122.
5. Chang KC, Yew WW, Zhang Y. 2011. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: A systematic review with meta-analyses. Antimicrob. Agents Chemother. 55:4499-4505. http://dx.doi.org/10.1128/AAC.00630-11.
6. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, III, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632. http://dx.doi.org/10.1126/science.1208813.
7. Alexander DC, Ma JH, Guthrie JL, Blair J, Chedore P, Jamieson FB. 2012. Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: A role for pncA but not rpsA. J. Clin. Microbiol. 50:3726-3728. http://dx.doi.org/10.1128/JCM.00620-12.
8. Juréen P, Werngren J, Toro JC, Hoffner S. 2008. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:1852-1854. http://dx.doi.org/10.1128/AAC .00110-08.
9. Rodrigues VDFS, Telles MA, Ribeiro MO, Cafrune PI, Rossetti ML, Zaha A. 2005. Characterization of pncA mutations in pyrazinamideresistant Mycobacterium tuberculosis in Brazil. Antimicrob. Agents Chemother. 49:444-446. http://dx.doi.org/10.1128/AAC.49.1.444-446.2005.
10. Portugal I, Barreiro L, Moniz-Pereira J, Brum L. 2004. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob. Agents Chemother. 48:2736-2738. http://dx.doi.org/10.1128/AAC.48.7. 2736-2738.2004.
11. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. 2010. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 48:300-301. http://dx.doi.org/10.1128/JCM.01775-09.
12. Tan Y, Hu Z, Zhao Y, Cai X, Luo C, Zou C, Liu X. 2012. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from southern China. J. Clin. Microbiol. 50:81-85. http://dx.doi.org/10.1128/JCM .05092-11.
13. Huang TS, Lee SSJ, Tu HZ, Tu HZ, Huang WK, Chen YS, Huang CK, Wann SR, Lin HH, Liu YC. 2003. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob. Agents Chemother. 47:3672-3673. http://dx.doi.org/10.1128/AAC.47.11.3672-3673.2003.
14. Jiang Y, Peng J, Yang F, Yu L, Wang Y, Jin Q. 2007. Molecular basis of Mycobacterium tuberculosis to pyrazinamide resistance. Prog. Microbiol. Immunol. 35:5-9. (In Chinese.)
15. Sun B, Yu H, Zhang K. 2007. Detection of pyrazinamide-resistant gene pncA of Mycobacterium tuberculosis isolates in Qingdao area. Acta Acad. Med. Qingdao Univ. 43:125-127. (In Chinese.)
16. Wu X, Zhang J, Zhong M, Yu W, Ding B, Zhang J, Jia S. 2000. Studies on pncA gene mutations in Mycobacterium tuberculosis isolates. Chin. J. Tuberc. Respir. Dis. 23:40-42. (In Chinese.)
17. Xu L, Yu H, Sun B, Zhou B, Zhang W. 2009. Detection of pncA gene mutation in Mycobacterium tuberculosis. Acta Acad. Med. Qingdao Univ. 45:424-426. (In Chinese.)
18. McCammon MT, Gillette JS, Thomas DP, Ramaswamy SV, Rosas II, Graviss EA, Vijg J, Quitugua TN. 2005. Detection by denaturing gradient gel electrophoresis of pncA mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis isolates from the United States-Mexico border region. Antimicrob. Agents Chemother. 49:2210-2217. http://dx.doi.org/10.1128/AAC.49.6.2210-2217. 2005.
19. Mirabal NC, Yzquierdo SL, Lemus D, Madruga M, Milián Y, Echemendía M, Takiff H, Martin A, Van der Stuyf P, Palomino JC, Montoro E. 2010. Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 48: 2729-2733. http://dx.doi.org/10.1128/JCM.00311-10.
20. Muthaiah M, Jagadeesan S, Ayalusamy N, Sreenivasan M, Prabhu SS, Muthuraj U, Senthilkumar K, Veerappan S. 2010. Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of Mycobacterium tuberculosis from South India. Int. J. Mol. Sci. 11:2670-2680. http://dx.doi.org/10.3390/ ijms11072670.
21. Zimic M, Sheen P, Quiliano M, Gutierrez A, Gilman RH. 2010. Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance. Infect. Genet. Evol. 10:346-349. http://dx.doi.org/10. 1016/j.meegid.2009.11.016.
22. Cui Z, Wang J, Lu J, Huang X, Zheng R, Hu Z. 2013. Evaluation of drug susceptibility testing methods of clinical Mycobacterium tuberculosis isolates to pyrazinamide. J. Clin. Microbiol. 51:1374-1380. http://dx.doi.org/10.1128/ JCM.03197-12.
23. Marttila HJ, Marjamäki M, Vyshnevskaya E, Vyshnevskiy BI, Otten TF, Vasilyef AV, Viljanen MK. 1999. pncA mutations in pyrazinamideresistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob. Agents Chemother. 43:1764-1766.
24. Park SK, Lee JY, Chang CL, Lee MK, Son HC, Kim CM, Jang HJ, Park HK, Jeong SH. 2001. pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. BMC Infect. Dis. 1:4. http://dx.doi.org/10.1186/1471-2334-1-4.
25. Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y. 1997. Characterization of pncA mutations in pyrazinamideresistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41: 540-543.
26. Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. 2010. Surveillance of pyrazinamide susceptibility among multidrugresistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol. 10:223-228. http://dx.doi.org/10.1186/1471-2180-10-223.
27. Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsåker T, Muthivhi T, Weyer K, Fourie PB, Grewal HM. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 46:3459-3464. http://dx.doi.org/10.1128/JCM .00973-08.
28. Simons SO, Van Ingen J, Van der Laan T, Mulder A, Dekhuijzen PN, Boeree MJ, Van Soolingen D. 2012. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 50:428-434. http://dx.doi.org/10.1128/JCM.05435-11.
29. Louw GE, Warren RM, Donald PR, Murray MB, Bosman M, Van Helden PD, Young DB, Victor TC. 2006. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis. 10:802-807.
30. Sekiguchi JI, Nakamura T, Miyoshi-Akiyama T, Kirikae F, Kobayashi I, Augustynowicz-Kopec E, Zwolska Z, Morita K, Suetake T, Yoshida H, Kato S, Mori T, Kirikae T. 2007. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamideresistant Mycobacterium tuberculosis strains. J. Clin. Microbiol. 45:2802-2807. http://dx.doi.org/10. 1128/JCM.00352-07.
31. Sheen P, Méndez M, Gilman RH, Peña L, Caviedes L, Zimic MJ, Zhang Y, Moore DAJ, Evans CA. 2009. Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. J. Clin. Microbiol. 47:2937-2943. http://dx.doi.org/10. 1128/JCM.01594-08.
32. Pelly S, Bishai WR, Lamichhane G. 2012. A screen for non-coding RNA in Mycobacterium tuberculosis reveals a cAMP-responsive RNA that is expressed during infection. Gene 500:85-92. http://dx.doi.org/10.1016/j .gene.2012.03.044.
33. Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. 2013. Contribution of moxifloxacin or levofloxacin in secondline regimens with or without continuation of pyrazinamide in murine tuberculosis. Am. J. Respir. Crit. Care Med. 188:97-102. http://dx.doi.org/10.1164/rccm.201212-2328OC.
34. Simons SO, Mulder A, Van Ingen J, Boeree MJ, Van Soolingen D. 2013. Role of rpsA gene sequencing in diagnosis of pyrazinamide resistance. J. Clin. Microbiol. 51:382. (Letter.) http://dx.doi.org/10.1128/JCM.02739-12.
35. Tortoli E. 2012. Phylogeny of the genus Mycobacterium: Many doubts, few certainties. Infect. Genet. Evol. 12:827-831. http://dx.doi.org/10.1016/j. meegid.2011.05.025.
36. Guo M, Sun ZH, Zhang Y. 2000. Mycobacterium smegmatis has two pyrazinamidase enzymes, PncA and PzaA. J. Bacteriol. 182:3881-3884. http://dx.doi.org/10.1128/JB.182.13.3881-3884.2000.
37. Ilina EN, Shitikov EA, Ikryannikova LN, Alekseev DG, Kamashev DE, Malakhova MV, Parfenova TV, Afanas'ev MV, Ischenko DS, Bazaleev NA, Smirnova TG, Larionova EE, Chernousova LN, Beletsky AV, Mardanov AV, Ravin NV, Skryabin KG, Govorun VM. 2013. Comparative genomic analysis of Mycobacterium tuberculosis drug resistant strains from Russia. PLoS One 8:e56577. http://dx.doi.org/10. 1371/journal.pone .0056577.